Welcome to our dedicated page for Pliant Therapeutics news (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics stock.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) is a clinical-stage biopharmaceutical company focused on integrin-based therapeutics for fibrotic diseases, solid tumors and muscular dystrophies. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Pliant’s clinical programs and corporate strategy evolve over time.
In its recent press releases, Pliant has highlighted several key themes. The company has reported interim and ongoing data from a Phase 1, open-label, dose-escalation trial of PLN-101095, an oral dual-selective inhibitor of integrins αvβ8 and αvβ1, in patients with advanced or metastatic solid tumors that are resistant or refractory to immune checkpoint inhibitors. These updates describe antitumor activity, including partial and complete responses in certain dose cohorts when PLN-101095 is combined with pembrolizumab, as well as safety and pharmacokinetic observations.
Pliant’s news flow has also covered developments in its bexotegrast (PLN-74809) program in idiopathic pulmonary fibrosis, including the termination and close-out of the BEACON-IPF Phase 2b/3 trial and the company’s decision to discontinue development of bexotegrast in IPF after reviewing safety and efficacy data. Additional communications have described scientific presentations at medical conferences, such as the American Thoracic Society International Conference, where the company has shared clinical and preclinical data related to fibrosis and biomarkers.
Corporate updates, including workforce and operational realignments, financial results and changes in executive roles, are also part of Pliant’s news record. Investors and followers of PLRX can use this page to review these categories of news—clinical trial updates, scientific presentations, program decisions and corporate announcements—in one place and revisit past disclosures as needed.
Pliant Therapeutics (Nasdaq: PLRX) has appointed Steve Krognes to its Board of Directors as announced on June 13, 2024. Krognes brings over 30 years of financial and corporate strategy experience in the biopharmaceutical industry. His prior roles include Chief Financial Officer at Denali Therapeutics and Genentech, and Global Head of Mergers and Acquisitions at Roche. Krognes' financial expertise and strategic leadership are expected to complement Pliant’s existing board, aiding in the company's evolution as a late-stage clinical entity. Currently, Krognes serves on several other boards, including Denali Therapeutics, Guardant Health, argenx, and ClavystBio. He holds an MBA from Harvard Business School and a B.S. in Economics from Wharton School, University of Pennsylvania.
Pliant Therapeutics (Nasdaq: PLRX) announced an inducement grant under Nasdaq Listing Rule 5635(c)(4) on June 12, 2024. The company granted stock options for 120,000 shares to Dr. Chohee Yun, the newly appointed Senior VP of Clinical Development. These options have an exercise price of $11.51 per share, aligned with the closing price on June 10, 2024. The options will vest over four years: 25% on the first anniversary and the remainder monthly over the next three years. The options have a 10-year term and are governed by the 2022 Inducement Plan.
Pliant Therapeutics presented promising data on their drug bexotegrast at the EASL International Liver Congress. Key findings included positive interim results from the Phase 2a INTEGRIS-PSC trial, showing that bexotegrast was well tolerated and effective in reducing markers of liver fibrosis over 12 weeks. Additionally, bexotegrast demonstrated a unique mechanism of action in targeting fibrogenic cells and inhibiting TGF-β signaling. These results further validate bexotegrast's potential as a treatment for fibrotic liver disease.
Pliant Therapeutics presented key data on their drug bexotegrast at the American Thoracic Society 2024 International Conference. The data includes clinical safety, imaging, and preclinical results supporting late-stage development of the drug for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Dr. Gregory P. Cosgrove highlighted that bexotegrast has been well tolerated in over 700 participants across 15 trials with mostly mild to moderate adverse events. Dr. Mahru C. An shared that bexotegrast effectively targets TGF-beta signaling in fibrogenic cells. Dr. Martin L. Decaris reviewed a post-hoc analysis showing significant modulation of plasma biomarkers in IPF patients over 12 weeks. Lastly, Dr. Jonathan G. Goldin reported a reduction in lung fibrosis progression and no increase in alveolar inflammation in bexotegrast-treated patients over 24 weeks.
Pliant Therapeutics announced positive topline data from a 12-week Phase 2a clinical trial of bexotegrast (PLN-74809) in patients with idiopathic pulmonary fibrosis (IPF). The study showed that bexotegrast 160 mg led to a reduction in total lung collagen compared to an increase in the placebo group, suggesting potential reversal of fibrosis. Improvements in forced vital capacity (FVC) and reduced cough severity were observed in bexotegrast-treated patients at all timepoints. The drug was well tolerated with no serious adverse events or discontinuations. The trial involved 10 patients, with 7 receiving bexotegrast and 3 on placebo. PET imaging was used to measure changes in lung collagen levels. The primary endpoint was the change in standardized uptake value (SUV) of a PET ligand that binds to type 1 collagen. Bexotegrast-treated patients showed a reduction in SUV, indicating a decrease in lung collagen. Additionally, improvements in fibrosis biomarkers, FVCpp, and patient-reported cough severity were noted.
Pliant Therapeutics, Inc. (PLRX) announces two poster presentations at the EASL International Liver Congress in Milan, Italy. The presentations focus on the updated safety and efficacy analysis of the INTEGRIS-PSC Phase 2a trial and the TGF-beta inhibition in human liver explant tissue with biliary fibrosis. The company continues to lead in the discovery of novel therapeutics for fibrotic diseases.
Pliant Therapeutics, a leader in fibrotic disease therapeutics, reported positive safety and efficacy data from Phase 2a trials. They accelerated the BEACON-IPF Phase 2b trial and received regulatory clearance for the PLN-101325 muscular dystrophy program. Financially, they reported a net loss of $47.0 million, with $483.9 million in cash and investments as of March 31, 2024.
Pliant Therapeutics, a clinical-stage biotechnology company focusing on fibrotic diseases, will participate in investor events in May 2024. The events include discussions with key company executives, offering insights into the company's progress and future plans.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Pliant Therapeutics (PLRX)?
What is the market cap of Pliant Therapeutics (PLRX)?
